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Abstract
Introduction High mobility group box 1 protein (HMGB1) is a
pleiotropic cytokine, recently implicated in the pathophysiology
of the systemic inflammatory response syndrome (SIRS) and
sepsis. Data from experimental sepsis models show that
administration of anti-HMGB1 antibodies significantly
decreased mortality, even when administration was delayed for
24 hours, providing a window of opportunity for therapeutic
intervention if transferred into a clinical setting. Whether genetic
variation in the human HMGB1 gene is associated with disease
susceptibility is unknown.
Methods We sequenced the HMGB1  gene in 239
prospectively monitored patients with SIRS admitted to an
intensive care unit and we measured the corresponding
HMGB1 serum concentrations. Blood donors served as control
individuals. Outcome parameters according to different
HMGB1 genotypes were compared.
Results Homozygosity and heterozygosity for a promoter variant
(-1377delA) was associated with a decreased overall 4-year
survival (15% versus 44%, hazard ratio = 1.80; P = 0.01) and
with a decreased number of SIRS criteria. Carriage of an exon 4
variant (982C>T) was significantly associated with an increased
number of SIRS criteria, a higher Simplified Acute Physiology
Score II score, a lower PaO2/FiO2  ratio and lower serum
HMGB1 levels (P  = 0.01), and with a significantly higher
probability of early death due to infection (P = 0.04). HMGB1
was undetectable in the control individuals.
Conclusion The present article is the first report of clinical
implications of variation in the human HMGB1  gene. Two
polymorphisms were determined as significant risk factors
associated with early and late mortality, which may provide
insight into the molecular background of SIRS and sepsis,
suggesting a possible role for HMGB1 genetics in future
prognostic evaluation.
Introduction
The systemic inflammatory response syndrome (SIRS), which
is the most common cause of death in intensive care units
(ICUs) [1], was formally defined in 1992 [2] as a clinical syn-
drome referring to the effects of severe systemic inflammation
associated with both infectious and noninfectious etiologies
[3]. The pathophysiology of SIRS is complex, with factors
related to the initial etiological event and the host's immune
system playing a role in determining the outcome (reviewed in
[4]). Why some patients die while other patients survive similar
insults is partly unknown, but may to some extent be explained
by the genetic variation. In recent years several studies have
been published showing the importance of variation in
cytokine genes on the inflammatory response affecting individ-
ual susceptibility to sepsis, risk of complications and death
(reviewed in [5]). The effect of genetic variation is an area of
intensive debate due to conflicting results [5].
High mobility group box 1 protein (HMGB1) is a highly con-
served [6] and ubiquitously expressed protein [7], originally
ELISA = enzyme-linked immunosorbent assay; HMGB1 = high mobility group box 1 protein; ICU = intensive care unit; PaO2/FiO2 = ratio between 
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discovered as a nonhistonal nuclear DNA binding protein [8].
The essential importance of HMGB1 as a pleiotropic cytokine
became apparent in a series of experiments showing that
HMGB1 was actively secreted from monocytes and macro-
phages in response to challenges with lipopolysaccharide and
by a TNFα-dependent mechanism [9]. Furthermore, the study
found that HMGB1 levels were significantly elevated in
patients who succumbed to sepsis, and that the administration
of HMGB1 in murine models caused sepsis-like symptoms
and death [9]. In experimental murine models of endotoxemia
[9] and sepsis, administration of anti-HMGB1 antibodies
decreased mortality significantly [9,10], even when administra-
tion was delayed for 24 hours [10], providing a window for
therapeutic intervention if transferred into a clinical setting.
These experiments showed that HMGB1 – in contrast to other
inflammatory cytokines, such as TNFα – is a late mediator of
inflammation. Besides being actively secreted, HMGB1 is
passively released from necrotic cells but not from apoptotic
cells, creating a signal for the organism to distinguish between
these two types of cell death [11]. Several studies have now
been published on HMGB1 and infection, and the general
consensus is that HMGB1 levels are increased in patients
with sepsis as compared with healthy control individuals
[9,12-17]. There is, however, evidence that HMGB1 is also
involved in the pathophysiology of a variety of other diseases
with no obvious infectious etiology: rheumatoid arthritis
[18,19], hemorrhagic shock [20], cerebral and myocardial
ischemia [21], acute lung injury [14] and acute pancreatitis
[22].
The human HMGB1 gene is located on chromosome 13, and
six polymorphic loci throughout the gene locus have recently
been identified [23]. In the present study we asked whether
HMGB1 variant alleles are associated with serum HMGB1
levels and outcome in patients with SIRS admitted to the ICU.
Materials and methods
Patients
The present study was based upon a previously published
cohort of consecutive patients > 17 years old, admitted to the
Intensive Care Unit, Glostrup University Hospital, Copenha-
gen, Denmark, who met the criteria for SIRS [24]. Patients
were assessed for Simplified Acute Physiology Score II
(SAPS II) [25] within 24 hours of admission to the ICU, and
the highest score was recorded. Peripheral blood samples for
serum measurements and DNA extraction were obtained
immediately after admission. Samples from 239 patients were
eligible for this study. Patients were excluded if the neutrophil
count was < 1.0 × 109 cells/l before the onset of sepsis, if the
infection was associated with burns, if the patient had sus-
pected or documented recent acute myocardial infarction, or
if there was a lack of commitment to full life-support measures
by the primary physician. Information about death during fol-
low-up was obtained from the Danish Central Office of Civil
Registration.
The control population consisted of 103 healthy Danish Cau-
casian blood donors, and has previously been published [23].
Furthermore, HMGB1 serum concentrations were measured
in 20 healthy Danish Caucasian blood donors.
Informed consent was obtained from all patients or from their
close relatives. The study was approved by the local ethics
committee.
Classification criteria for SIRS, sepsis, severe sepsis and 
septic shock
SIRS was defined as outlined by the American college of
Chest Physicians/Society of Critical Care Medicine Consen-
sus Conference [2]. Sepsis was defined as SIRS with a doc-
umented or clinically suspected infection, while severe sepsis
was defined as the presence of sepsis with at least one of the
following organ dysfunction criteria developing within 24
hours of enrolment in the study: arterial systolic blood pressure
< 90 mmHg for at least 1 hour, despite appropriate fluid resus-
citation or vasopressor therapy; urine output < 0.5 ml/kg for >
1 hour, despite hydration; PaO2/FiO2 ratio ≤ 40 kPa; acute
deterioration of mental status (Glasgow Coma Score < 14);
unexplained metabolic acidosis with pH ≤ 7.30 or base deficit
≥ 5.0 mM in association with plasma lactate ≥ 1.6 mM; or
hepatobilliary dysfunction with serum bilirubin > 34 μM and no
evidence of pre-existing hepatobilliary disease. Septic shock
was defined as sepsis with hypotension and one of the above
listed organ dysfunction criteria.
Genotyping
Reference single nucleotide polymorphism numbers (rs) are
provided for genetic variants. All PCR and sequencing primers
were synthesised by DNA-Technology A/S (Aarhus, Den-
mark). The DNA sequence containing the -1615A>G
(rs1412125) and -1377delA (rs41369348) genetic variants
was amplified using primer set A; the sequence containing the
1747delT (rs55946320), 1779 T>G (rs41433050),
1808C>G (rs55832802), 1822G>A (rs41534245) and
1888insT (rs41497949) variants was amplified using primer
set B; and the 2351insT (rs41376448) and
4519_4521delGAT (rs56178645) variants were amplified
using primer set C (Table 1). Forward primers contained a 5'-
T7 tag (5'-TAA TAC GAC TCA CTA TAG GG-3').
PCR amplification was performed in a volume of 12 μl, con-
taining 0.25 μM forward and reverse primers, 0.50 μl DNA, 2
mM MgCl2, 0.27 mM dNTP, 67 mM KCl, 27 mM Tris-HCl, pH
8.4, and 0.03 U Platinum Taq DNA polymerase (Invitrogen
Corp., Carlsbad, CA, USA). Amplification was carried out on a
GeneAmp PCR System 9700 (Applied Biosystems, Foster
City, CA, USA) under the following cycling conditions: 94°C
for 2 minutes; 35 cycles of 94°C for 30 seconds, 60°C for 1Available online http://ccforum.com/content/12/3/R83
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minute and 72°C for 1 minute; and 72°C for 5 minutes. The
PCR products were sequenced using the ABI BigDye cycle
sequencing terminator kit (Applied Biosystems) according to
the manufacturer's protocol.
The DNA regions containing the -1615 A>G, -1377delA,
4519_4521delGAT and 2351insT variants were sequenced
in the forward direction with 0.16 μM biotin-conjugated T7
sequence primers, and were subsequently purified using
streptavidin sepharose beads. The DNA region containing the
1747delT, 1779T>G, 1808C>G, 1822G>A and 1888insT
variants was sequenced in the reverse direction with 0.16 μM
primer set B reverse primer and was purified by ethanol pre-
cipitation preceded by ExoSAP-IT (USB Corp., Cleveland,
OH, USA) clean up, according to the manufacturer's protocol.
Streptavidin sepharose high-performance bead (GE health-
care Bio-Sciences Corp., Piscataway, NJ, USA) purification
was performed by incubating 2.5 μl PCR product with 3 μl
beads and 25 μl binding buffer (3 mM Tris-HCl, pH 7.5, 0.3
mM ethylenediamine tetraacetic acid, 0.6 M NaCl) for 5 min-
utes under continuous agitation. The beads were hereafter
picked up by the Vacuum Prep Tool (Biotage AB, Uppsala,
Sweden) and were rinsed by sequential 10-second aspira-
tions of 70% ethanol, 0.2 M NaOH and 70% ethanol, followed
by release into 15 μl deionised formamide (Amresco, Solon,
OH, USA).
Ethanol precipitation was performed by adding 96% EtOH
with 25 μl of 0.1 M NaOAc (pH 4.6) to 10 μl sample, with sub-
sequent centrifugation for 30 minutes at 2,500 × g and for 1
minute inverted at 150 × g. Thereafter, 50 μl of 70% EtOH
was added and the sample was centrifuged for 5 minutes at
2,500 g and for 1 minute inverted at 150 × g. Finally, 15 μl
deionised formamide was added.
After purification, the sequence analysis was performed on an
ABI Prism 3100 Genetic Analyzer (Applied Biosystems). The
DNA sequences were aligned using BioEdit software version
7.0.5.3 [26] and polymorphisms were confirmed visually from
sequence electropherograms. New genetic variants were con-
firmed by reverse sequencing and were submitted to the
dbSNP database [27].
The -196C>A (rs41477046), 982C>T (rs1060348),
1177G>C (rs3742305) and 3814C>G (rs2249825) variants
were genotyped by using the PSQ 96 MA pyrosequencing
platform (Biotage AB) according to the manufacturer's proto-
Table 1
PCR and pyrosequencing primers
Genetic variant PCR Pyrosequencing primer
Primer set Forward primer Reverse primer
Sequencing
-1615A>G A 5'-ATG TGC ATG TGT GAT ATA TTG 
TCC-3'
5'-GTT ATA TCA GTG CTT TAT GAA ACT 
AC-3'
-1377delA
1747delT B 5'-CAA AGT TTT ATG CAA GGA GGG 
TG-3'
5'-GTC CAT TCA GGG CGA TCT C-3'
1779T>G
1808C>G
1822G>A
1888insT
4519_4521delGAT C 5'-AAA GTT CTG CCA TGT TCT ATT TC-
3'
5'-CAG GAC AGG GCT ATC TAA AG-3'
2351insT
Pyrosequencing
-196C>A 5'-CTC TTT GCC CGG CAT ACA CA-3' 5'-TCC TGA CCA GAG CCC GTT T-3' 5'-TTG ATG ACG TGT CCC-3'
3814C>G 5'-GTC TGA TTT TAC GGA GGT TGA-3' 5'-CCT TTG CCC ATG TTT AGT TAT T-3' 5'-TAC TTT GGT TTT CAT TCC-
3'
982C>T 5'-TGT TCA TCT AGG GTT CTA GCT-3' 5'-CCT TTG ATT TTT GGG CGA TAC-3' 5'-TTA GTT CGG CCT TCT T-3'
1177G>C 5'-AAC TGG GAG AGA TGT GGA ATA-3' 5'-CAA TCA TAC ATC TGG CGT ACT-3' 5'-GGT TTG CTT GGT AAA 
ATG-3'
Forward primers from primer sets A, B and C contain a 5'-T7 sequence (5'-TAA TAC GAC TCA CTA TAG GG-3'). The 5' ends of all of the PCR reverse primers used 
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cols. PCR was performed in a volume of 30 μl under the same
conditions as described above. The PCR and pyrosequencing
primers are presented in Table 1.
Serum high mobility group box 1 protein
HMGB1 serum concentrations were measured using the
HMGB1 ELISA Kit II (Shino-Test Corporation, Tokyo, Japan)
according to the manufacturer's protocols.
Statistical analysis
The inferred haplotypes and linkage disequilibrium, expressed
as D' Lewontin's coefficient and the squared correlation coef-
ficient R2 quantified betweenall pairs of biallelic loci, were esti-
mated using the SNPAlyzeprogram version 4.0 (Dynacom,
Yokohama, Japan). The Hardy-Weinberg equilibriumwas ana-
lysed using gene frequencies obtained by simple genecount-
ing and the chi-square test with Yates' correction
forcomparing observed and expected values. Fisher's exact
test was used to compare frequencies, and the Wilcoxon test
and the Kruskall-Wallis test were used to compare continuous
data. Survival was estimated by the Kaplan-Meier method, and
comparisons were made with the log-rank test. Cumulative
incidence estimates were calculated to allow for death from
causes other than infection to be treated as a competing risk
[28], and curves were compared using Gray's k-sample test
[29]. Cox regression analysis was performed when appropri-
ate. All P values were two-sided and P < 0.05 was considered
significant.
Results
Genetic variation in the HMGB1 gene
Table 2 presents the frequency of the polymorphisms in the
HMGB1 gene in 239 SIRS patients and in 103 healthy control
individuals. There was no significant difference between the
SIRS patients and the control population in the frequency of
polymorphisms (P > 0.05).
The -196C>A, 1779T>G and 1822insT mutations were not
observed in the SIRS patients, while the 1888insT mutation
was observed in two SIRS patients and was therefore treated
as a polymorphism, although not meeting the formal require-
ment of an allele frequency ≥ 1%. The novel polymorphism
1747delT, entailing a deletion of a single thymine in a
sequence of 11 thymine nucleotides in intron 1 (Figure 1), was
observed in the SIRS patients. The control subjects were rean-
alysed and, upon reverse sequencing, four individuals were
found heterozygous for 1747delT. Two novel genetic variants,
1808C>G and 4519_4521delGAT, were identified once in
two different SIRS patients, and were therefore classified as
mutations. The 4519_4521delGAT entailed a deletion of the
trinucleotide sequence GAT in exon 5 (Figure 1), leading to
deletion of an aspartate amino acid from the acidic tail of the
HMGB1 protein.
All polymorphisms adhered to the Hardy-Weinberg equilib-
rium expectations (P  < 0.05). The pairwise investigation
between the eight polymorphic loci indicated strong linkage
Table 2
Distribution of genotypes
Polymorphism rs number Control population SIRS population
-1615A>G 1412125 A/A A/G G/G A/A A/G G/G
24.0 47.0 29.0 24.0 48.0 28.0
-1377delA 41369348 A/A A/- -/- A/A A/- -/-
87.0 13.0 0.0 89.5 10.0 0.5
1747delT 55946320 T/T T/- -/- T/T T/- -/-
96.0 4.0 0.0 97.0 3.0 0.0
1888insT 41497949 -/- -/T T/T -/- -/T T/T
99.0 1.0 0.0 99.0 1.0 0.0
3814C>G 2249825 C/C C/G G/G C/C C/G G/G
47.0 47.0 6.0 53.0 41.0 6.0
982C>T 1060348 C/C C/T T/T C/C C/T T/T
92.0 8.0 0.0 95.0 5.0 0.0
1177G>C 3742305 G/G G/C C/C G/G G/C C/C
47.0 46.0 7.0 53.0 41.0 6.0
2351insT 41376448 -/- -/T T/T -/- -/T T/T
50.0 45.0 5.0 57.0 38.0 5.0
Observed frequencies (%) of polymorphisms in 103 healthy Danish Caucasian control individuals and in 239 systemic inflammatory response syndrome (SIRS) 
patients (P > 0.05). rs number, reference single nucleotide polymorphism number.Available online http://ccforum.com/content/12/3/R83
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disequilibrium between several genotype variants (Table 3).
Only genetic variants defined as polymorphisms were used in
the construction of haplotypes. Out of 43 and 45 possible
inferred haplotypes in the SIRS and control populations,
respectively, the polymorphisms only segregated as 13 and
15 distinct haplotypes. The most common haplotypes (fre-
quency > 3%) in the control and SIRS populations are shown
in Figure 1. Observed haplotype frequencies were similar in
both populations – except for haplotype 2, which was
observed with a significantly (P = 0.006) higher frequency in
the control population than in the SIRS patients.
Patient characteristics
Out of the 239 patients with SIRS who were enrolled in this
study, 63 patients had SIRS without infection and 24 patients
fulfilled the criteria for sepsis, 87 patients for severe sepsis
and 65 patients for septic shock. The median follow-up was
698 days (range, 1 to 1,458 days), with an overall survival of
41%. Patients were admitted to the ICU for a median of 3 days
(range, 0 to 38 days) and 48 patients died while in the ICU.
There were no significant differences in the distribution of pol-
ymorphisms between the SIRS without infection group, the
sepsis group, the severe sepsis group and the septic shock
Table 3
Pairwise linkage disequilibrium (expressed by D' Lewontin's coefficient/squared correlation coefficient R2) between 
polymorphisms
-1615A>G -1377delA 1747delT 1888insT 3814C>G 982C>T 1177G>C
-1377delA 1/0.062
1747delA 1/0.0137 0.0658/0.0010
1888insT 1/0.00453 0.4401/0.0141 -1/0.00005
3814C>G -0.7193/0.1736 -1/0.0208 -1/0.0046 -0.1868/0.00005
982C>T -1/0.0239 -1/0.00148 -1/0.000327 -1/0.0001 -0.7274/0.00493
1177G>C -0.7234/0.1775 -1/0.021 -1/0.00465 -0.2114/0.00007 1/0.9894 -0.2228/0.00047
2351insT -0.6433/0.1202 -1/0.018 -1/0.00398 0.0443/0.00003 0.9503/0.7816 0.0462/0.00018 0.9626/0.7935
Figure 1
Schematic illustration of the high mobility group box 1 protein gene locus Schematic illustration of the high mobility group box 1 protein gene locus. The most common inferred haplotypes (frequency > 3%) in both the con-
trol population and the systemic inflammatory response syndrome (SIRS) population are shown. Modified from Ferrari and colleagues [41]. Bold, 
location of polymorphisms; italic, location of mutations; underline, mutations only found in the control population; solid boxes, exons I to V. *Haplo-
type was statistically more frequent in the SIRS population (P = 0.006) as compared with the control population.Critical Care    Vol 12 No 3    Kornblit et al.
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group. Baseline characteristics and overall survival probabili-
ties are outlined according to admission status in Table 4.
Influence of HMGB1 genotype on survival
Stratification of the patients according to HMGB1 genotype
revealed a significantly lower overall survival in patients with
the -1377delAA/- or -1377delA-/- genotypes as compared with
patients with the -1377delAA/A genotype (15% versus 44%, P
= 0.01) (Figure 2a). For statistical purposes, the one patient
homozygous for -1377delA-/- was included in the -1377delAA/
-  group in all analyses. The decreased overall survival in
patients with the -1377delAA/- or -1377delA-/- genotypes was
discernible in the survival curves after approximately day 50
(Figure 2a), but did not become significant until the end of fol-
low-up. In Cox regression analysis, the -1377delAA/-  or -
1377delA-/- genotype was an independent risk factor signifi-
cantly associated with death, in both a restricted survival
model and in an expanded model, including known factors
associated with survival (age and number of SIRS criteria)
(Table 5).
Although no other genotypes were associated with differ-
ences in survival, patients with the 982C/T genotype had near-
significant (P = 0.08) decreased day 28 survival as compared
with patients with the 982C/C genotype (Figure 2b). In order
to allow for the presence of competing risks, the cumulative
incidence was calculated. This incidence revealed a signifi-
cantly (P = 0.04) higher probability of death due to infection in
patients with the 982C/T genotype as compared with patients
with the 982C/C genotype (50% versus 20%).
There were no significant differences in age, gender and type
of admission between patients in the -1377delAA/- group, the
-1377delA-/- group or the 982C/T group and the rest of the
cohort. Haplotypes one to six from the SIRS population were
not associated, independent of the -1377delAA/-  or -
1377delA-/- and 982C/T genotypes, with any disease param-
eters or outcomes.
Serum HMGB1 levels, SIRS criteria, SAPS II score and 
PaO2/FiO2 ratio
The serum HMGB1 levels in the 20 healthy control individuals
were all below the detection level of the assay (0.3125 ng/μl),
and were significantly different (P < 0.001) from the mean
serum HMGB1 level of the patient population. The mean
serum HMGB1 levels tended to increase when moving from
patients with only SIRS to patients with sepsis of increasing
severity, although only reaching a near-significant level (P =
Table 4
Patient baseline characteristics and mortality according to admission status
Variable SIRS without infection group Sepsis group Severe sepsis group Septic shock group
Number of patients (%) 63 (26.4%) 24 (10.0%) 87 (36.4%) 65 (27.2%)
Age (years) 58.5 ± 18.2 54.8 ± 15.4 63.1 ± 14.9 64.1 ± 15.1
Type of admission
Acute surgery 33 (13.8) 11 (4.6) 32 (13.4) 26 (10.9)
Elective surgery 4 (1.7) 1 (0.4) 2 (0.8) 0 (0)
Medical 26 (10.9) 12 (5.0) 53 (22.2) 39 (16.3)
Chronic disease
Metastatic cancer 0 0 0 1
Hematological malignancy 1 0 2 0
SAPS II scorea 32.7 ± 15.8 23.4 ± 8.4 40.4 ± 12.1 45.7 ± 14.4
PaO2/FiO2 ratioa 183 ± 93 351 ± 53 152 ± 89 137 ± 82
Serum HMGB1 (ng/μl) 0.94 ± 1.81 1.49 ± 3.15 1.38 ± 2.73 1.79 ± 4.00
Number of SIRS criteriaa
2 31 (13.0) 8 (3.3) 17 (7.1) 5 (2.1)
3 20 (8.4) 8 (3.3) 31 (13.0) 19 (7.9)
4 12 (5.0) 8 (3.3) 39 (16.3) 41 (17.2)
Overall survival (%)
Day 28 87 88 62 65
Follow-up time 52 71 25 41
Data presented as n (%), mean ± standard deviation or percentage. aComparison of systemic inflammatory response syndrome (SIRS) without infection versus sepsis, 
severe sepsis and shock, and comparison of sepsis versus severe sepsis versus septic shock, P < 0.01. HMGB1, high mobility group box 1 protein; PaO2/FiO2 = ratio 
between partial pressure of oxygen and fraction of inspired oxygen; SAPS II, Simplified Acute Physiology Score II.Available online http://ccforum.com/content/12/3/R83
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0.08) when comparing SIRS patients with sepsis patients
regardless of severity (Table 4). No significant difference in
serum HMGB1 levels was seen between survivors and non-
survivors (P = 0.13). There was no correlation between serum
HMGB1 levels and the number of SIRS criteria, the SAPS II
score or the PaO2/FiO2 ratio.
The serum HMGB1 levels in patients with the 982C/T geno-
type were significantly lower (P = 0.008) as compared with
patients with the C/C genotype, but were not different from
healthy control individuals (P = 0.19). No significant difference
(P = 0.37) was found between patients with the -1377delAA/
A genotype and the -1377delAA/- or -1377delA-/- genotype
(Table 6). Patients with the 982C/T genotype had a higher
number of SIRS criteria (P = 0.002), a lower PaO2/FiO2 ratio
(P = 0.003), and a tendency towards a higher SAPS II score
(P = 0.108), as compared with patients with the C/C geno-
type. Patients with the -1377delAA/- or -1377delA-/- genotype
had a lower number of SIRS criteria (P = 0.008), a tendency
towards a lower PaO2/FiO2 ratio (P = 0.07), and no difference
in SAPS II score (P = 0.73), as compared with patients with
the -1377delAA/A genotype (Table 6).
Discussion
The pathophysiology of SIRS and sepis is complex, and the
recognition that inherited traits influence individuals' suscepti-
bility and ability to respond appropriately to inflammation [30]
has prompted several studies exploring the association
between genotypes and outcome. Polymorphisms in innate
immune receptors and in both proinflammatory and anti-inflam-
matory cytokines have been extensively studied in relation to
SIRS and sepsis (reviewed in [5]).
In the present study, several associations were observed
revealing the importance of the genetic variation in the
HMGB1 gene. The -1377delAA/- genotype or the -1377delA-/
- genotype showed a significant association with delayed mor-
tality, independent of age and number of SIRS criteria. In
agreement with this, a significant association with lower
number of SIRS criteria and a tendency to a higher PaO2/FiO2
ratio was observed, predicting better early survival. The impact
of the -1377delA polymorphism on mortality was already dis-
cernable at approximately day 50 after admission, suggesting
that the initial insult related to the ICU admission renders the
patients carrying the -1377delA polymorphism genotype more
susceptible to subsequent events associated with fatal out-
come.
The cause of adverse late events was not recorded in the
present study design, and remains to be further clarified in fol-
low-up studies. Of interest, however, is the observation that
the survival of patients carrying the deleterious genotype never
reached a constant plateau but decreased throughout the fol-
low-up period – which could be explained by the patients
being rendered partly immunocompromised during the initial
SIRS insult, leading to an increased morbidity and mortality in
the period after discharge from the hospital. The small study
size probably conveyed insufficient statistical power for signif-
icance to be reached before the end of the follow-up. The
importance of the near-significant association between
982C>T heterozygosity and early mortality (day 28) was sup-
ported by a significantly increased mortality due to infectious
causes, and by a consistent association with disease severity
parameters predictive of lower survival – such as an increased
number of SIRS criteria, a tendency towards an increased
SAPS II score and a lower PaO2/FiO2 ratio [31]. The relatively
Figure 2
Influence of HMGB1 genotype on survival Influence of HMGB1 genotype on survival. (a) Overall survival during 
the follow-up period according to the -1377delA genotype. (b) 28-day 
survival according to the 982C>T genotype.Critical Care    Vol 12 No 3    Kornblit et al.
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low number of patients included in the present study is an
obvious weakness, calling for further studies to confirm to
what extent the genetic polymorphisms in the HMGB1 gene
can be utilised as severity markers in SIRS and sepsis.
Several clinical studies have been published to date with data
on serum HMGB1 levels in various inflammatory settings.
Although the studies are heterogeneous in design and popu-
lation size, a common finding is that patients with infection
and/or SIRS have elevated levels of serum HMGB1 as com-
pared with healthy control individuals [9,12-17,32,33]. Con-
flicting results have been published, however, regarding the
correlation between serum HMGB1 levels and disease etiol-
ogy, severity and mortality, with only a few studies observing a
significant increase in serum HMGB1 levels in nonsurvivors
with sepsis as compared with survivors [9,32]. Furthermore,
only one study found a marginally significant difference in
serum levels between infected and noninfected patients with
SIRS [15]. The majority of reports do not show a correlation
between disease severity and serum HMGB1 levels
[12,15,17,32].
Our study is consistent with most of these findings, with lower
serum HMGB1 in healthy control individuals as compared with
patients, no difference in serum HMGB1 levels according to
disease severity, and no correlation with number of SIRS cri-
teria, SAPS II score and PaO2/FiO2 ratio – although a ten-
dency towards increased levels was observed in patients with
sepsis, irrespective of severity, as compared with patients with
SIRS without infection. While no association was found
according to the 1377delA genotype, the 982C>G genotype
was significantly associated with serum HMGB1 levels. Of
particular interest in this regard was that HMGB1 could not be
detected in 20 healthy control individuals, showing that that
the phenotype effect of the HMGB1  polymorphism on the
HMGB1 serum concentration may only become apparent in
disease settings. The finding of lower HMGB1 levels in
patients with a higher risk of mortality during their early disease
course was surprising, but is in line with reports where nonsig-
nificant trends towards lower serum levels were observed in
patients with septic shock and severe sepsis, as compared
with patients with less severe disease [12,15]. Furthermore, in
a recent study of sepsis, severe cardiovascular failure was sig-
nificantly associated with lower levels of serum HMGB1 [33].
These findings support the concept of immune paresis, sug-
gesting a primary rather than secondary hypoimmune
response, where survival among sepsis patients is associated
with the recovery of the inflammatory system and not of the
anti-inflammatory system [34].
The conflicting results observed across studies could be
explained by additional factors other than the heterogeneity of
Table 6
Classification of serum HMGB1, number of SIRS criteria, SAPS II score and PaO2/FiO2 ratio according to the HMGB1 982C>T and -
1377delA genotypes
Variable 982C>T genotype -1377delA genotype
C/C C/T A/A A/- or -/-
Serum HMGB1 (ng/μl) 1.45 ± 3.05 0.28 ± 0.96* 1.36 ± 2.78 1.61 ± 4.43
Number of SIRS criteria 3.13 ± 0.81 3.83 ± 0.39* 3.21 ± 0.80 2.76 ± 0.78*
SAPS II 37.8 ± 15.2 43.9 ± 12.3 38.2 ± 15.3 36.8 ± 13.8
PaO2/FiO2 ratio 164 ± 94 89 ± 38* 158 ± 96 182 ± 63
Data presented as mean ± standard deviation. *P = 0.01. HMGB1, high mobility group box 1 protein; PaO2/FiO2 = ratio between partial pressure of oxygen and 
fraction of inspired oxygen; SAPS II, Simplified Acute Physiology score II; SIRS, systemic inflammatory response syndrome.
Table 5
Cox regression survival models
Hazard ratio 95% confidence interval P value
Restricted model
-1377delA genotype 1.80 1.13 to 2.87 0.01
Expanded model
-1377delA genotype 1.84 1.14 to 2.96 0.028
Age 1.04 1.03 to 1.05 < 0.001
Number of SIRS criteria 1.42 1.13 to 1.80 0.003
SIRS, systemic inflammatory response syndrome.Critical Care    Vol 12 No 3    Kornblit et al.
Page 9 of 10
(page number not for citation purposes)
study populations. HMGB1 acts as a late mediator of sepsis,
detectable in septic mice after 8 hours and reaching peak lev-
els after 16 hours [9]. In clinical studies where HMGB1 levels
were measured at different time points, two studies report
increasing levels during admission [12,17] and one study
reports stable levels that persist throughout the first week and
after discharge [32]. This opens up the possibility that study
patients were either sampled too early or too late in their dis-
ease course. In the present study population, the SIRS and
sepsis diagnoses were established during the initial 24 hours
in the ICU, making it possible that infected patients where
diagnosed too early in their disease course to be correctly
identified as SIRS with infection. When comparing serum
HMGB1 levels across the studies, a striking difference is
observed. In studies using ELISA methods [15-17], as in the
present study, much lower serum levels are observed com-
pared with studies using blotting techniques [9,12,32]. This
discrepancy could be responsible for some of the conflicting
results, since it is not known whether the current methods
detect different subsets of the protein. Passively released
HMGB1 and actively secreted HMGB1 differ at the molecular
level [35], and it has been suggested that HMGB1 biological
activities could vary depending on these differences [36].
In the present study a total 10 genetic variants were identified,
eight of which were classified as polymorphisms and two as
mutations. Out of the eight genetic variants classified as poly-
morphisms, frequency data on seven of the variants have pre-
viously been published [23]. The novel 1747delT
polymorphism was primarily observed by sequencing in the
SIRS population, and was confirmed upon reanalysis in the
control population. The frequencies of the polymorphisms in
the SIRS population and in the control population were similar
(Table 2). The observed slight but significant variation in the
distribution of inferred haplotypes between the populations
could be attributed to the population sizes, and was without
significant impact on disease parameters or outcome.
In accordance with the high degree of HMGB1 structural con-
servation and with the location of the majority of previously
identified genetic variants [23], the novel 1808C>G mutation
was located in a noncoding region (Figure 1). By contrast, the
novel 4519_4521delGAT mutation was located in a coding
region of the gene, and entails a structural change; namely, the
deletion of an aspartate amino acid residue from the acidic tail
of the finished HMGB1 protein. Previous reports show that
both the structure-selective binding of HMGB1 to DNA
[37,38] and its interaction with various transcriptional factors
[39,40] are highly dependent on the length of the acidic tail.
Apart from changing the inherent DNA binding properties of
the protein, therefore, the deletion could also cause changes
in acetylation and thereby the premise for its release and bio-
logical properties [35,36].
Conclusion
The present study is the first report on the implications of the
genetic variation in the human HMGB1 gene in a population
of critically ill patients admitted to an ICU with SIRS and sep-
sis. Genetically determined risk factors associated with early
and late mortality and death due to infection were revealed,
explaining some of the inherited risk in this heterogeneous
patient population. Associations between genetic variation
and disease severity parameters were also established. Fur-
ther studies, both clinical and experimental, are therefore
needed to confirm the significance of these findings and to
explain their molecular background.
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